Kornimate/medical-research-clean huggingface dataset:
telehealth interventions for daily routine activities in children and adolescents with disabilities

Conditions: Children With Physical Disabilities; Adolescents With Physical Disabilities

Summary: performance of activities during daily routines is an important outcome of rehabilitation services for children and adolescents with physical disabilities, independent of their health condition or functional level. the aim of this study was to evaluate the effect of a telehealth intervention using whatsapp text, audio, and video messaging on achievement of individualized goals for performance of activities in daily routines in children and adolescents with physical disabilities. the intervention is an eight-week participation-based intervention for children and adolescents with physical disabilities consisted of a goal-oriented, family-centred, collaborative, strength-based, ecological, and self-determined intervention.

performance of activities during daily routines is an important outcome of rehabilitation services for children and adolescents with physical disabilities, independent of their health condition or functional level. the international classification of functioning, disability, and health defines activity as whole-body actions and participation as involvement in life situations. telehealth is a method of service delivery that might enable service providers and families to collaborate on goals for performance of activities during daily routines. the aim of this study was to evaluate the effect of a telehealth intervention using whatsapp text, audio, and video messaging on achievement of individualized goals for performance of activities in daily routines in children and adolescents with physical disabilities. the intervention is an eight-week participation-based intervention for children and adolescents with physical disabilities consisted of a goal-oriented, family-centred, collaborative, strength-based, ecological, and self-determined intervention. it is a pragmatic intervention where goals for physical activities in daily routines took into consideration the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. the therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. there are two follow-ups: first after twelve weeks y the last two years later.

Eligibility criteria:
inclusion criteria: * participants between five and 21 years old. * participants with a physical disability. * participants with the ability to walk with or without an assistive device. exclusion criteria: * participants with orthopedic surgery within the past 6 months. * participants with a health condition limiting physical activity. * participants with contraindications to exercise. * participants unable to understand the instructions to complete the outcome measures.

Keywords: children adolescents disability physical therapy participation physical activity
pain self-management and patient-oriented dosing for pain and in retention opioid treatment

Conditions: Opioid Use Disorder; Chronic Pain

Summary: this study seeks to improve the treatment of chronic pain in people who are taking buprenorphine (also known as suboxone, subutex, zubsolv). the research study is testing two different interventions along with usual clinical care: 1. pain self-management (psm): an educational program in which individuals with chronic pain work with a trained pain coach and a pain peer to explore strategies to effectively manage the daily problems that arise from chronic pain. 2. patient-oriented dosing (pod): an alternative dosing of buprenorphine which will be adjusted based on pain levels. the interventions will take place over a period of 12 weeks (3 months). additionally, participants will complete surveys every 3 months for a period of 1 year (total of 5 survey visits). participants will receive $50 compensation for each survey visit completed (up to $250 over one year) and can receive up to an additional $100 bonus compensation. there are risks associated with participating in the study, including breach of confidentiality, psychological distress caused by discussing difficult topics, and risks associated with the pod intervention.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. adults at least 18 years old from participating clinics 2. ability to speak, read, and understand english 3. capable of providing informed consent 4. access to phone and/or internet 5. documented diagnosis of opioid use disorder (oud) 6. within \<180 days (6 months) of a new treatment episode, ideally within 90 days (3 months) * new treatment episode is defined as not having received prescribed buprenorphine treatment in an outpatient setting for oud in the prior 30 days (1 month) 7. on a stable dose of an oral or sublingual buprenorphine mono or combination product (\<4 times per day, daily dosage \<32 mg) for at least 7 days during incident new episode of care 8. have high impact chronic pain (grade 3), based on the graded chronic pain scale-revised (gcps-r) exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. under 18 years of age 2. have cancer-related pain 3. are currently in jail, prison, or overnight facility as required by court of law or have pending legal action that could prevent participation in study activities 4. currently prescribed 32mg of an oral or sublingual buprenorphine mono or combination product 5. currently prescribed an injectable formulation of buprenorphine 6. pregnancy or intention to become pregnant within 4 months of enrollment 7. currently prescribed naltrexone 8. history of hypersensitivity to buprenorphine that a clinician-determined caused serious rash/hives/pruritus, bronchospasm, angioneurotic edema, or anaphylactic shock individuals with common comorbidities, such as depression, anxiety, or alcohol, methamphetamine, and other substance use disorders will not be excluded.

Keywords: pain self-management buprenorphine
a registry study of sanwujiaowan capsule used in clinical real world

Conditions: Rheumatism; Osteoarthritis

Summary: the purpose of this study is get to know what and how sanwujiaowan capsule in hospital results in drug-induced liver injury or adverse drug reactions from a cohort event monitoring as registration research.

in order to improving monitoring drug-induced liver injury or adverse drug reactions of chinese medicine containing radix polygoni multiflori in hospital, registry study is suitable method in this area. otherwise, nested case control study is used to find out the mechanism of drug-induced liver injury. calculate the incidence of drug-induced liver injury or adverse drug reactions is one of the main aims for this study. safety surveillance on chinese medicine containing radix polygoni multiflori is an important problem that needs to be sorted out through large sample observational study. according to the relevant regulations of the cfda, 3000 cases need to be registered at least. the aim population is who using sanwujiaowan capsule 's with abnormal liver function before medication from june 2017 to december 2018.

Eligibility criteria:
inclusion criteria: patients using sanwujiaowan capsule 's with abnormal liver function before medication from june 2017 to december 2018. exclusion criteria: none
inguinal hernia study using biodesign ihm

Conditions: Inguinal Hernia

Summary: aim is to evaluate outcomes of inguinal hernia repair incorporating the standard lichtenstein (open) repair using biodesign ihm in a double blind (physician evaluator and patient will be blinded), randomized, prospective comparative study with polypropylene mesh. primary outcome is recurrence at 1 year. hernia recurrence will be confirmed via ultrasound or ct scan.


Eligibility criteria:
inclusion criteria: * 18 years of age * diagnosis of unilateral inguinal hernia repair * able to provide written consent exclusion criteria: * incarcerated hernia * allergic or religious beliefs that disallow porcine material * previous hernia repair on the designated hernia site * class iv or v anesthesia requirements * bowel obstruction * peritonitis * life expectancy \< 3 years

Keywords: inguinal hernia polypropylene biodesign ihm lichtenstein
dietary supplementation with low-dose omega-3 reduces salivary tnf-α levels in patients with chronic periodontitis

Conditions: Chronic Periodontitis

Summary: the investigators primary objective in this clinical intervention study, therefore, was to explore the impact of omega-3 pufas in conjunction with scaling and root planing on salivary markers (in patients with chronic periodontitis.

thirty systemically healthy subjects with chronic periodontitis were enrolled and randomly allocated into two groups. the control group (n=15) was treated with scaling and root planing (srp)+placebo whereas the test group (n=15) was treated with srp and dietary supplementation of low-dose omega-3 pufas (6.25 mg epa and 19.19 mg dha). clinical parameters were taken at baseline, 1, 3 and 6 months following therapy. saliva samples were obtained at the same time intervals and analyzed for tumor necrosis factor-α (tnf-α) and superoxide dismutase (sod).

Eligibility criteria:
inclusion criteria: * patients diagnosed with chronic periodontitis * had at least nine posterior teeth (not including third molars and teeth with bridges and crowns) * with 5-7 mm pocket depth * three teeth with 6 mm or more of probing attachment loss enrolled in the study exclusion criteria: * patients were excluded on the basis of periodontal surgery within the last year; * srp as part of initial periodontal therapy within the past 6 months; * history of diabetes, any diseases or disorders that compromise wound healing, any history of acute or chronic inflammatory disease, * any oral mucosal inflammatory condition (e.g., aphthous, lichen planus, leukoplakia, and oral cancer) and use of aspirin * other non-steroidal anti-inflammatory drugs or antibiotics within the last 6 months.

Keywords: saliva omega-3
effects of multiple nasal exposures to house dust mite allergen on nasal and body inflammation and airway sensitivity

Conditions: Allergic Rhinitis

Summary: this study will evaluate whether multiple nasal antigen challenges with dust mite allergen produces increases in nasal symptoms and local allergic inflammatory cells in the nose and the blood.


Eligibility criteria:
inclusion criteria: * healthy non-smoking subjects with a history of allergic rhinitis consistent with dust mite allergy showing * a positive skin prick test to dust mite at or within the 12 months before study start * demonstrate symptomatic worsening after graded nasal allergen challenge exclusion criteria: * subjects found to be very sensitive to house dust mites (if the skin prick test produces a wheal of mean with a diameter greater than 11 mm). * presence of any respiratory disease other than a history of mild stable asthma not requiring regular treatment. * any known contraindications for methacholine challenge testing other protocol-defined inclusion/exclusion criteria may apply.

Keywords: allergic rhinitis dust mites ige il-13 nasal inflammation
addiction risk: the influence of mindset induction on the effect of a brief intervention to reduce alcohol use

Conditions: Alcohol Drinking

Summary: brief interventions (bi) based on motivational interviewing are effective to reduce alcohol use. in this study the investigators test the hypothesis that that an open mindset increases the positive effects of bi. patients who are newly admitted to the psychotherapy outpatient clinic are routinely screened for risky alcohol use. all patients with risky alcohol use are eligible to the study and all receive the who's assist-linked bi. participants receive a brief mindset induction prior to receiving bi. they are are randomly assigned to either the induction of an open or a closed mindset according to gollwitzer. the investigators measure the change in alcohol-related risk perception, treatment motivation and real alcohol drinking.


Eligibility criteria:
inclusion criteria: * admitted to treatment at psychotherapy outpatient clinic exclusion criteria: * alcohol use disorder * substance use disorder
suboptimal responders to adefovir switching to entecavir

Conditions: Hepatitis B, Chronic

Summary: switching to entecavir will result in superior antiviral efficacy as compared to continuing with adefovir in patients with a suboptimal response to adefovir


Eligibility criteria:
inclusion criteria: * chronic infection with hepatitis b virus (hbv)(detectable hepatitis b surface antibody (hbsag) at screening and at least 24 weeks prior to screening, or detectable hbsag for \<24 weeks and negative for immunoglobulin m core antibody) * documentation of hepatitis b e antigen (hbeag) positive or negative status * naive to nucleoside/nucleotide analogues, with the exception of adefovir * suboptimal response to adefovir treatment * no lamivudine/telbivudine, entecavir, or adefovir resistance-associated substitutions at screening * male or female gender, aged 16 years and older * compensated liver function * serum alanine aminotransferase level \<10\*upper limit of normal at screening exclusion criteria: * women who are pregnant or breastfeeding * evidence of decompensated cirrhosis * coinfection with hiv, hepatitis c virus, or hepatitis d virus * recent history of pancreatitis (within 24 weeks prior to the first dose of study medication) * chronic renal insufficiency, defined as a creatinine clearance \<50 ml/min * current abuse of illegal drugs or alcohol, sufficient in the investigator's opinion to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis * other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications * serum creatinine level \>1.5 mg/dl; hemoglobin level \ 100 ng/ml * except adefovir, any prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis b (eg, lamivudine, entecavir), or any other experimental anti-hbv antiviral, or any china traditional medicine * therapy with interferon, thymosin alpha, or other immunostimulators within 24 weeks of randomization * required chronic administration of medications that cause immunosuppression, that are associated with a high risk of nephrotoxicity or hepatotoxicity, or that affect renal excretion.
investigation into the differentiation of tumour and healthy brain tissue using multi-exponential t2 components

Conditions: Glioma

Summary: the purpose of this study is to see if a specialized imaging technique using mri called multi-exponential t2 component analysis can reliably differentiate between normal brain and brain tumour.

existing methods of contouring tumours for radiation therapy involve manual interpretations of qualitative diagnostic images. these methods, being qualitative, do not offer a consistent and reproducible platform for contouring, making it difficult to evaluate the effects of contouring choices on treatment outcome. t2 component analysis in mri has the potential to offer a quantitive basis for identifying tumor tissue- this potential is investigated in this pilot study.

Eligibility criteria:
inclusion criteria: * eighteen years of age or older * clinical subjects must have not yet begun radiation therapy * must have signed our study-specific consent form exclusion criteria: -

Keywords: magnetic resonance imaging glioma
meopa versus local anesthesia for analgesia during chorionic villus sampling.

Conditions: Pain

Summary: determine if efficiency of meopa anesthesia is at least equivalent to local anesthetics into the chorionic villus sampling in the first trimester of pregnancy

compare anxiety discomfort and side effects

Eligibility criteria:
inclusion criteria: * pregnant * 18 and over * monofetal pregnancy * chorionic villus sampling medical indication without contra indication * informed consent signature exclusion criteria: * pregnant under 18 * multiple pregnancies * pregnancy inferior 11 aw * no informed consent signature
a switch study of bms-337039 in schizophrenic out-patients

Conditions: Schizophrenia

Summary: the purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing efficacy and/or safety/tolerability issues while on risperidone.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of schizophrenia as defined by dsm-iv-tr2 criteria * out-patients who have been taking risperidone for minimum 6 weeks who are not optimally controlled and/or experiencing safety/tolerability issues with risperidone * men and women, aged 18 - 65 years exclusion criteria: * patients who are at risk for committing suicide * patients with a diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic symptoms, or organic brain syndromes * meeting dsm-iv-tr criteria for any significant psychoactive substance use disorder within the 3 months prior to screening * treatment-resistant to antipsychotic medication
biofeedback and cortical excitability

Conditions: Incontinence; Constipation

Summary: looking for a modification of the cortical excitability of the motor area corresponding to the external anal sphincter after biofeedback sessions.

introduction: nervous control of pelvic floor is not much known. the dysfunction of this musculature, and particularly of the external anal sphincter, is a frequent cause of anal incontinence and/or dyschesia. biofeedback training is often offered to patients suffering from incontinence or constipation. however, its mechanisms of action is still controversial. objective of the study: to compare excitability of the cortical area responsible for control volunteer of the external anal sphincter in healthy subjects before and after 4 biofeedback sessions. subjects and methodology: we offer to perform two groups of 12 healthy subjects (one active and one control group) without any neurological or digestive disease and having never performed biofeedback. in each group, cortical excitability will be evaluated by cortical magnetic stimulation (curve intensity/amplitude, silent period, inter-stimulus period, motor threshold) before and after 4 biofeedback sessions (one session by week) in active group or 4 placebo sessions (placebo group). we hope to show a modification of cortical excitability in subjects performing biofeedback compared to others.

Eligibility criteria:
inclusion criteria: * healthy volunteers between 18 years old and 35 years old * right handed\* exclusion criteria: * pregnancy * pace-maker or other metallic piece implanted in the body * neurological disease * epilepsy * digestive disease * traumatic delivery * anorectal surgery * biofeedback * psychiatric disease * treatment anti-epileptic, hypnotic, psychotropic * participation to a previous protocol within 1 month

Keywords: biofeedback anal sphincter cortical excitability magnetic stimulation incontinence constipation
a phase i trial of simmitinib in advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is an open label, multi-center, phase i study of oral simmitinib in subjects with advanced solid tumors including gastric cancer.

this is an open label, multi-center, phase i study of oral simmitinib in subjects with advanced solid tumors including gastric cancer \[including gastroesophageal cancer\], cholangiocarcinoma, lung squamous cell carcinoma, urothelial transitional cell carcinoma, and estrogen-receptor-positive breast cancer patients \[er+\], etc. this phase i study will evaluate the safety, tolerability, pharmacokinetics and the preliminary efficacy of the fgfr/kdr/csf1r multi-target inhibitor simmitinib.

Eligibility criteria:
inclusion criteria: * voluntary written informed consent of the patient obtained before any study-specific procedure； * eastern cooperative oncology group (ecog) performance status of 0 to 1; * patients with histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to standard therapy or for whom no standard therapy exist; * adequate washing period from last anti-tumor therapy; * measurable disease according to response evaluation criteria in solid tumors (recist), version 1.1; * the expected survival time for more than 12 weeks; * adequate bone marrow, hepatic, renal, pancreas, and coagulation function, blood phosphorus and calcium in the normal range. exclusion criteria: * prior treatment with selective fgfr inhibitors or multi-target kinase inhibitors with fgfr as the main target; * unrecovered from any drug-related adverse event to grade ≤ 1 according to the national cancer institute-common terminology criteria for adverse events (nci-ctcae) v.3.0 derived from any previous anti-tumor treatment, excluding alopecia, pigmentation, or other toxicity with little safety risk for subjects; * active central nervous system (cns) metastases (brain or leptomeningeal metastases, etc.); * any other history of malignancy within 3 years; * congenital coagulation abnormalities. active bleeding or previous history of massive bleeding (\>30ml within 3 months), history of hemoptysis (more than 5ml fresh bleeding within 4 weeks); * corneal diseases of clinical significance. there is a history of retinal pigment epithelial detachment or evidence of the presence of retinal pigment epithelial detachment. history of age-related macular degeneration or evidence of age-related macular degeneration exists； * subjects with impaired cardiac function or heart disease of clinical significance; * pregnant or lactating women.
family centered services in cerebral palsy

Conditions: Cerebral Palsy

Summary: to examine the family-centered service characteristics of physiotherapy and rehabilitation services received by children with cerebral palsy (cp) and to investigate the affecting factors.

children with cerebral palsy (cp) attend special education and rehabilitation centers to receive physiotherapy and rehabilitation (pt) services, and it is very important for parents to be informed about the services offered in these centers. our aim in the study was to examine which factors affect family-centered characteristics and parental perceptions in the pt services received by children with cp. for this purpose, 100 children diagnosed with cp between the ages of 2-18 and their parents were included in the study. the measure of processes care (mpoc) survey was used to assess parents' perceptions of the family-centered features of (pt) services. these perceptions were examined to determine whether they vary depending on the child's age, functional level, parents' educational status, the impact of their disabled children, and health-related quality of life. the family impact scale was used to measure parents' level of influence from their disabled children, and the nottingham health profile survey was used to evaluate their health-related quality of life.

Eligibility criteria:
inclusion criteria: * having a child aged between 2 and 18 years diagnosed with cerebral palsy * receiving physiotherapy and rehabilitation services for at least one year * the family's consent to participate in the study and their approval for their child to be assessed by the researcher physiotherapist and for their information to be collected within the scope of the study exclusion criteria: * parents over the age of 65 * parents who do not speak turkish * having another child with a disability

Keywords: physiotherapy rehabilitation family centered services impact family cerebral palsy